01—Abstract
Summary
Summary of the 10-Q filed November 2, 2026. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories, Inc. reported strong financial results for the nine months ended September 30, 2026, demonstrating robust revenue growth and improved profitability.
Total revenue increased by 11.2% to $3.57 billiona, driven primarily by the Companion Animal Group (CAG) segment, which saw a 11.3% revenue increase. This growth was fueled by strong performance in CAG Diagnostics recurring revenue, including IDEXX VetLab consumables and reference laboratory services, supported by higher volumes and pricing. The Water and Livestock, Poultry and Dairy (LPD) segments also contributed positively with revenue growth of 11.3% and 8.7%, respectively.
Net income for the nine-month period rose by 15.1% to $934.0 millionb, and diluted earnings per share increased to $11.75. The company's operational efficiency improved, with gross profit margin expanding by 110 basis points to 63.4%.
Significant investments were made in the acquisition of CoVet AI Inc. for approximately $250 millionc, expanding the company's AI-native software offerings in the veterinary space. Despite increased operating expenses, particularly in general and administrative functions due to acquisitions and technology investments, the company maintained strong income from operations, growing by 14.0% to $1.19 billion.
02—Key points
Key Highlights
- Total revenue for the first nine months of 2026 increased by 11.2% year-over-year to $3.57 billion.
- Net income for the nine-month period grew by 15.1% to $934.0 million, with diluted EPS reaching $11.75.
- The Companion Animal Group (CAG) segment remains the primary growth driver, with revenue up 11.3% driven by recurring diagnostics and services.
- Acquisition of CoVet AI Inc. for approximately $250 million to enhance AI and software capabilities in the veterinary market.
- Gross profit margin improved by 110 basis points to 63.4% due to higher revenues and operational efficiencies.
- Strong operating cash flow generation of $1.06 billion for the nine-month period.
- The company maintained a healthy leverage ratio of 0.5-to-1 as of September 30, 2026, indicating a solid financial position.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2026, IDEXX Laboratories kept $0.26.
- Revenue$1.21B100.0%
- Cost of revenue−$449.9M37.1%
- Gross profit$764.3M62.9%
- Operating costs−$361.9M29.8%
- Operating income$402.3M33.1%
- Interest, other & tax−$85.2M7.0%
- Net income$317.1M26.1%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2026filed November 2, 2026Financial Statements
Q3 FY2026 against Q3 FY2025
| Line item | Q3 FY2026Q3 FY2025 | Change |
|---|---|---|
| Revenue | $1.21B$1.11B | +9.9% |
| Cost of Revenue | $449.94M$421.88M | +6.6% |
| Gross Profit | $764.30M$683.35M | +11.8% |
| R&D Expenses | $68.82M$63.41M | +8.5% |
| Operating Expenses | $361.95M$328.51M | +10.2% |
| Operating Income | $402.35M$354.85M | +13.4% |
| Net Income | $317.14M$274.61M | +15.5% |
| EPS (Basic) | $4.02$3.43 | +17.2% |
| EPS (Diluted) | $4.01$3.40 | +17.9% |
| Shares Outstanding (Basic) | 78.83M80.10M | −1.6% |
| Shares Outstanding (Diluted) | 79.05M80.67M | −2.0% |
05—Questions
Frequently Asked Questions
What are the main drivers of IDEXX's revenue growth in this period?
IDEXX's revenue growth is primarily driven by its Companion Animal Group (CAG) segment, specifically from recurring diagnostics revenue such as IDEXX VetLab consumables and reference laboratory services. Higher volumes, effective pricing strategies, and customer retention are key contributors. The Water and Livestock, Poultry and Dairy (LPD) segments also show positive revenue trends due to increased volumes and prices.
How did the acquisition of CoVet AI Inc. impact the financial results?
The acquisition of CoVet AI Inc. for approximately $250 million, which closed on September 15, 2026, is expected to enhance IDEXX's AI and software offerings in the veterinary market. While the impact on the nine-month results was immaterial due to the timing of the acquisition, it represents a strategic investment to expand the company's technology capabilities and future growth potential.
What is the company's liquidity and capital resource outlook?
IDEXX maintains a strong liquidity position. As of September 30, 2026, the company had $197.5 million in cash and cash equivalents and significant borrowing availability of $773.2 million under its credit facility. Management believes these resources, combined with operating cash flows, are sufficient to fund operations, capital requirements, and growth initiatives for the foreseeable future. The company also repurchased $810 million of its common stock in the first nine months of 2026.
What is the outlook for profitability and margins?
Profitability remains strong, with net income increasing by 15.1% year-over-year. Gross profit margin expanded by 110 basis points to 63.4%, reflecting increased revenues and operational productivity. While operating expenses, particularly general and administrative costs, saw an increase due to strategic investments and acquisitions, the company's overall income from operations grew by 14.0%, indicating effective cost management and a positive outlook for sustained profitability.
06—Continue